+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Immune Disorders Drugs Market Research Reports

From
From
Adult-onset Still's Disease - Epidemiology Forecast to 2032 - Product Thumbnail Image

Adult-onset Still's Disease - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
From
From
Tadekinig Alfa - Emerging Insight and Market Forecast - 2030 - Product Thumbnail Image

Tadekinig Alfa - Emerging Insight and Market Forecast - 2030

  • Report
  • April 2021
  • 35 Pages
  • Global
From
Graves' Disease - Pipeline Insight, 2025 - Product Thumbnail Image

Graves' Disease - Pipeline Insight, 2025

  • Drug Pipelines
  • July 2025
  • 60 Pages
  • Global
From
Chronic Spontaneous Urticaria - Pipeline Insight, 2025 - Product Thumbnail Image

Chronic Spontaneous Urticaria - Pipeline Insight, 2025

  • Clinical Trials
  • July 2025
  • 80 Pages
  • Global
From
Nasal Polyps - Pipeline Insight, 2025 - Product Thumbnail Image

Nasal Polyps - Pipeline Insight, 2025

  • Clinical Trials
  • July 2025
  • 60 Pages
  • Global
From
Sjogren's Syndrome - Pipeline Insight, 2025 - Product Thumbnail Image

Sjogren's Syndrome - Pipeline Insight, 2025

  • Clinical Trials
  • July 2025
  • 80 Pages
  • Global
From
Vitiligo - Pipeline Insight, 2025 - Product Thumbnail Image

Vitiligo - Pipeline Insight, 2025

  • Clinical Trials
  • July 2025
  • 80 Pages
  • Global
From
Peanut Allergy - Pipeline Insight, 2025 - Product Thumbnail Image

Peanut Allergy - Pipeline Insight, 2025

  • Clinical Trials
  • July 2025
  • 60 Pages
  • Global
From
Mucopolysaccharidosis Type I- Pipeline Insight, 2025 - Product Thumbnail Image

Mucopolysaccharidosis Type I- Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Autoimmune Encephalitis (AE) - Pipeline Insight, 2025 - Product Thumbnail Image

Autoimmune Encephalitis (AE) - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Autoimmune Gastritis - Pipeline Insight, 2025 - Product Thumbnail Image

Autoimmune Gastritis - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Anti-inflammatory - Pipeline Insight, 2025 - Product Thumbnail Image

Anti-inflammatory - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Chronic Gout - Pipeline Insight, 2025 - Product Thumbnail Image

Chronic Gout - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
House Dust Mite Allergy - Pipeline Insight, 2025 - Product Thumbnail Image

House Dust Mite Allergy - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
HIV-associated Lipodystrophy - Pipeline Insight, 2025 - Product Thumbnail Image

HIV-associated Lipodystrophy - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Interleukin-10 (IL-10) Receptor Agonist - Pipeline Insight, 2025 - Product Thumbnail Image

Interleukin-10 (IL-10) Receptor Agonist - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Loading Indicator

The Immune Disorders Drugs market is a sector of the pharmaceutical industry that focuses on the development and production of drugs to treat immune system disorders. These drugs are used to treat a variety of conditions, including allergies, asthma, autoimmune diseases, and cancer. Immune Disorders Drugs are designed to target specific parts of the immune system, such as cytokines, antibodies, and T-cells, to reduce inflammation and improve the body's ability to fight off infection. The Immune Disorders Drugs market is highly competitive, with many large pharmaceutical companies competing for market share. Some of the major players in the market include AbbVie, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Merck, Novartis, Pfizer, and Roche. These companies are constantly researching and developing new drugs to treat immune system disorders, as well as improving existing treatments. Show Less Read more